Deutsche Bank
EIDX

Deutsche Bank’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Deutsche Bank’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-9,072
Closed -$1.2M – 4807
2020
Q4 		$1.2M Buy
9,072
+2,062
+29% +$182K ﹤0.01% 2326
2020
Q3 		$354K Buy
7,010
+765
+12% +$34.4K ﹤0.01% 2852
2020
Q2 		$297K Buy
6,245
+2,278
+57% +$106K ﹤0.01% 2911
2020
Q1 		$194K Sell
3,967
-618
-13% -$31.5K ﹤0.01% 2961
2019
Q4 		$262K Buy
4,585
+1,490
+48% +$73.8K ﹤0.01% 3059
2019
Q3 		$110K Sell
3,095
-1,788
-37% -$69.8K ﹤0.01% 3501
2019
Q2 		$149K Sell
4,883
-13,479
-73% -$365K ﹤0.01% 4006
2019
Q1 		$428K Buy
18,362
+12,283
+202% +$197K ﹤0.01% 3552
2018
Q4 		$83K Sell
6,079
-10,342
-63% -$131K ﹤0.01% 4295
2018
Q3 		$163K Buy
+16,421
New +$270K ﹤0.01% 4320

Deutsche Bank's EIDX Position: Q1 2021 in Review

Deutsche Bank sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 9,072 shares — an estimated $1.2M sold.

Deutsche Bank first reported a position in EIDX in Q3 2018 and held it in 10 quarters. The position peaked at $1.2M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

  • Deutsche Bank reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Deutsche Bank sold 9,072 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $1.2M.
  • Deutsche Bank first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2018 and held it in 10 quarters.
  • Deutsche Bank's Eidos Therapeutics, Inc. Common Stock position peaked at $1.2M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Deutsche Bank's 13F filing for Q1 2021, filed 13 May 2021.